Osteoarthritis Therapeutics Market: How New Treatments Are Changing the Future of Joint Care

Osteoarthritis is becoming an increasingly important healthcare concern as populations age, obesity rates rise, and more people live with long-term joint pain and mobility problems. While conventional medicines remain central to osteoarthritis management, the treatment landscape is gradually expanding toward injectable therapies, biologics, regenerative medicine, and disease-modifying approaches.

This evolution is creating new opportunities in the Osteoarthritis Therapeutics Market, as pharmaceutical and biotechnology companies invest in treatments that can provide better symptom control and potentially address the underlying progression of joint disease.

The global Osteoarthritis Therapeutics Market was valued at approximately USD 10,560 million in 2025 and is projected to reach USD 19,610 million by 2035, expanding at a 6.39% CAGR from 2026 to 2035. 

Why Is the Osteoarthritis Therapeutics Market Growing?

Osteoarthritis is the most common joint disorder worldwide, with the patient population continuing to expand as life expectancy increases. Aging is one of the major factors driving the disease burden, while obesity, sedentary lifestyles, sports injuries, and occupational joint stress are contributing to additional cases.

The market is being supported by several important trends:

• Rising prevalence of osteoarthritis among aging populations

• Increasing obesity rates and lifestyle-related risk factors

• Growing demand for non-surgical pain management

• Greater use of injectable therapies

• Advances in disease-modifying osteoarthritis drugs

• Increasing research into regenerative medicine and biologics

• Growing healthcare expenditure and access to orthopedic care

These factors are creating demand for both established treatments and emerging therapeutic approaches. 

Knee Osteoarthritis Remains the Largest Segment

Among different joint types, knee osteoarthritis accounted for 48.60% of the market in 2025, making it the largest segment.

The knee is particularly vulnerable because it carries substantial body weight and is exposed to repeated mechanical stress. Aging, excess weight, previous injuries, and physical inactivity can further increase the risk of joint degeneration.

As more patients seek alternatives to surgery, demand is expanding across oral medicines, injections, biologic therapies, regenerative approaches, physical therapy, and other supportive treatments.

Hip and hand osteoarthritis also represent important areas of treatment demand as the global patient population continues to grow. 

NSAIDs Continue to Lead Drug-Class Demand

NSAIDs accounted for approximately 31.80% of the market in 2025, making them the leading drug-class segment.

Their widespread use is largely associated with their established role in managing osteoarthritis-related pain and inflammation. Both prescription and over-the-counter formulations are available across many markets.

However, long-term use can present safety concerns, particularly among older patients. Gastrointestinal, cardiovascular, and kidney-related risks associated with certain NSAIDs are encouraging continued interest in alternative treatment options.

This creates an opportunity for pharmaceutical companies to develop therapies that offer effective symptom management with improved long-term tolerability. 

Non-Surgical Treatment Is Becoming Increasingly Important

Many patients prefer to manage osteoarthritis symptoms before considering joint replacement surgery. This is supporting demand for non-surgical approaches such as oral medicines, injections, physical therapy, exercise, and weight management.

Corticosteroid and hyaluronic acid injections are commonly used for moderate-to-severe osteoarthritis, while emerging biologic and regenerative approaches are expanding the range of available treatment options.

The growing focus on early intervention is also encouraging healthcare providers to identify and manage osteoarthritis before patients reach advanced stages of joint damage.

Disease-Modifying Therapies Could Transform Osteoarthritis Care

One of the biggest unmet needs in osteoarthritis treatment is the limited availability of therapies that can directly slow disease progression.

Most established treatments primarily focus on reducing pain and improving mobility rather than preventing cartilage degeneration.

This is driving interest in disease-modifying osteoarthritis drugs (DMOADs).

Researchers are investigating therapies that target inflammation, cartilage preservation, structural joint damage, and other mechanisms associated with disease progression.

Successful development of DMOADs could significantly expand the therapeutic landscape and address a major unmet need in osteoarthritis care. 

Regenerative Medicine Is Opening New Treatment Possibilities

Regenerative medicine has become one of the most closely watched areas within the osteoarthritis therapeutics industry.

Research is advancing across several approaches, including:

• Platelet-rich plasma (PRP)

• Stem cell therapies

• Gene therapies

• Biologic agents

• Cartilage regeneration

• Tissue-engineering technologies

These approaches are being investigated for their potential to support cartilage preservation, joint repair, and improved function.

The growing clinical pipeline and increasing investment from pharmaceutical and biotechnology companies are helping expand research into next-generation osteoarthritis treatments. 

At the same time, clinical evidence, regulatory requirements, treatment costs, and long-term outcomes remain important considerations for the wider adoption of regenerative therapies.

Oral Therapies Still Dominate, but Injectable Treatments Are Advancing

By route of administration, oral treatments accounted for 58.40% of the market in 2025.

Oral medicines remain widely used because they are familiar, accessible, and relatively convenient for patients.

However, injectable treatments are gaining attention as healthcare providers look for targeted approaches to managing joint pain and inflammation.

Intra-articular corticosteroids, hyaluronic acid, biologic therapies, and emerging regenerative treatments are contributing to the development of this segment.

The growing interest in injectable therapies also reflects the industry's broader shift toward targeted and potentially more personalized treatment approaches. 

Hospitals Remain the Leading End-User Setting

Hospitals accounted for approximately 42.50% of the market in 2025, making them the leading end-user segment.

Hospitals provide access to orthopedic specialists, diagnostic facilities, medication-based treatment, injections, surgery, and rehabilitation services.

This makes them particularly important for patients with moderate-to-severe osteoarthritis who require multidisciplinary or advanced care.

At the same time, specialized orthopedic and outpatient care settings are becoming increasingly relevant as healthcare systems look for more convenient and cost-effective treatment pathways.

Hospital Pharmacies Continue to Play a Major Distribution Role

Hospital pharmacies held approximately 39.60% of the market in 2025, supported by high prescription volumes and the availability of specialized orthopedic care.

Hospital-based distribution remains important for patients receiving advanced treatments, injectable therapies, and medicines prescribed through specialist consultations.

As digital healthcare and pharmaceutical distribution continue to evolve, other channels may gain importance, particularly in markets where online pharmacy services and home delivery are becoming more established.

Personalized Treatment Could Improve Osteoarthritis Management

Osteoarthritis can vary considerably between patients. Disease severity, affected joint, age, body weight, activity level, previous injuries, and other factors can influence how the disease progresses and how patients respond to treatment.

This is increasing interest in personalized osteoarthritis treatment.

Advances in imaging, biomarkers, digital health, and patient data could help physicians identify disease progression earlier and select therapies more effectively.

Personalized treatment could also support the development of targeted therapeutics and help identify patients who are most likely to benefit from specific interventions. 

North America Remains the Largest Regional Market

North America accounted for approximately 39% of global Osteoarthritis Therapeutics Market revenue in 2025, making it the largest regional market.

The region benefits from a large aging population, high healthcare expenditure, advanced healthcare infrastructure, and strong adoption of innovative treatment options.

The North American market was valued at approximately USD 4,118 million in 2025. 

The United States represents the majority of the regional market. Its growth is supported by a large osteoarthritis patient population, established pharmaceutical companies, advanced orthopedic care, and continued clinical research into new treatment approaches.

Asia Pacific Offers Significant Growth Potential

Asia Pacific accounted for approximately 24% of the global market in 2025 and is expected to experience the fastest growth during the forecast period.

The regional market is projected to increase from approximately USD 2,534 million in 2025 to USD 4,706 million by 2035. 

Several factors are supporting this expansion:

• Rapid population aging

• Increasing obesity rates

• Growing healthcare expenditure

• Improving access to orthopedic care

• Rising awareness of osteoarthritis

• Expanding adoption of advanced therapies

The combination of a large patient population and improving healthcare infrastructure makes Asia Pacific an important growth region for pharmaceutical and biotechnology companies.

India and Other Emerging Markets Create New Opportunities

Emerging economies are becoming increasingly important as healthcare infrastructure improves and access to orthopedic treatment expands.

India accounted for approximately 14.20% of the Asia Pacific market in 2025, with growth supported by increasing osteoarthritis prevalence, rising obesity, improving healthcare access, and expanding orthopedic services. 

Across Asia Pacific, Latin America, and the Middle East, increasing healthcare investment and greater awareness of musculoskeletal disorders are creating opportunities for both conventional and advanced osteoarthritis therapies.

What Challenges Could Limit Market Growth?

Despite strong demand, the industry continues to face several challenges.

One of the most important is the limited availability of broadly approved disease-modifying therapies. Most existing treatments focus on symptom management rather than reversing or significantly slowing cartilage degeneration.

Other challenges include:

• Safety concerns associated with long-term drug use

• High costs of advanced therapies

• Expensive joint replacement procedures

• Reimbursement limitations

• Complex clinical development requirements

• Regulatory challenges for emerging therapies

• Unequal access to advanced treatment

These factors can influence both patient access and the speed at which innovative therapies reach the market. 

DMOAD Development Represents a Major Opportunity

The development of disease-modifying osteoarthritis drugs is one of the most important opportunities in the market.

Pharmaceutical companies are investigating therapies designed to address cartilage preservation, inflammation pathways, and structural joint damage.

A successful DMOAD could change the way osteoarthritis is managed by providing an option that goes beyond temporary symptom relief.

This opportunity could also create demand for complementary technologies, including biomarkers, advanced imaging, companion diagnostics, and personalized treatment strategies. 

Growing Investment in Regenerative and Biologic Therapies

Investment in regenerative medicine and biologic therapies is expanding the osteoarthritis treatment pipeline.

PRP, stem cell therapies, gene therapies, and biologic agents are being studied for their potential to support cartilage regeneration and joint preservation.

Although these approaches are at different stages of clinical development and adoption, continued research is expanding the number of potential treatment strategies available to patients.

For pharmaceutical and biotechnology companies, this creates opportunities to develop differentiated therapies aimed at specific disease mechanisms and patient populations.

What Is the Future of the Osteoarthritis Therapeutics Market?

The future of osteoarthritis treatment is likely to involve a combination of established medicines, injectable therapies, biologics, regenerative approaches, disease-modifying drugs, and personalized treatment strategies.

The market is projected to grow from USD 10,560 million in 2025 to USD 19,610 million by 2035, reflecting continued demand for both conventional and emerging therapies. 

Several developments are likely to shape the next phase of the industry:

1. Development of DMOADs targeting disease progression

2. Expansion of regenerative medicine and biologic therapies

3. Increasing adoption of injectable treatments

4. Growth of personalized treatment approaches

5. Greater focus on early diagnosis

6. Expansion of specialized orthopedic care

7. Increasing healthcare investment in emerging markets

8. Integration of digital health and diagnostic technologies

Conclusion

The Osteoarthritis Therapeutics Market is evolving as healthcare providers and pharmaceutical companies look beyond conventional symptom management.

NSAIDs and other established therapies will continue to play an important role, but growing interest in DMOADs, biologics, regenerative medicine, injectable therapies, and personalized treatment is creating a broader therapeutic landscape.

North America currently represents the largest regional market, while Asia Pacific offers significant growth potential as aging populations, healthcare investment, and access to advanced treatment continue to increase.

For pharmaceutical companies, biotechnology firms, healthcare providers, and investors, the development of treatments that can provide longer-lasting benefits and potentially address disease progression will remain an important area of focus.

Explore the Full Osteoarthritis Therapeutics Market Analysis

For detailed market size, segmentation, regional forecasts, treatment trends, competitive analysis, opportunities, and strategic insights, explore the Osteoarthritis Therapeutics Market report from BrandEssence Research.